This is a phase II precision medicine cancer trial with nearly 40 treatment arms. See study details. Patients with advanced solid tumors, lymphomas, or myeloma may be eligible, once they have progressed on standard treatment for their cancer or if they have a rare cancer for which there is no standard treatment. Some arms have exceptions. Each arm targets a unique gene abnormality known to drive cancer growth. Many of these driver mutations occur only rarely in patients, as shown by the posted frequency rates. These are the rates found in the first 6,000 patients tested in this trial. See the table below for the open treatment arms.

Total accrual: 1127 as of 07/31/2020

http://ecog-acrin.org/trials/nci-match-eay131

For more information: Cincinnati Children’s Division of Hematology / Oncology | Phone: 513-636-2799 | Emailcancer@cchmc.org

 

TARGET

STUDY / ID

ACCRUAL

AGENT

DISEASE EXCEPTIONS

DATE ACTIVATED

STATUS

EGFR Activating Mutations
(0.05% frequency)

A

35 (19)

Gilotrif® (afatinib)

Small cell cancer, non-small cell lung cancer (NSCLC)

8/12/2015

OPEN

MET amplification
(0.51% frequency)

C1

50 (35)

Xalkori® (crizotinib)

None

5/31/2016

OPEN

MET Exon 14 Deletion
(0.61% frequency)

C2

35 (20)

Xalkori® (crizotinib)

None

5/31/2016

OPEN

EGFR T790M (with/without an activating mutation) or Rare Activating Mutations of EGFR
(0.11% frequency)

E

35 (11)

AZD9291

NSCLC

8/12/2015

OPEN

mTOR Mutations
(0.31% frequency)

L

35 (20)

TAK-228 (formerly MLN0128)

None

3/13/2017

OPEN

TSC1 or TSC2 mutations
(1.11% frequency)

M

49 (35)

TAK-228 (formerly MLN0128)

None

3/13/2017

OPEN

Smoothened (SMO) or Patched 1 (PTCH1) Mutations
(0.42% frequency)

T

35 (34)

Erivedge® (vismodegib)

Basal cell skin cancer

2/23/2016

OPEN

cKIT Mutations
(0.11% frequency)

V

35 (10)

Sutent® (sunitinib malate)

Gastrointestinal stromal tumors (GIST), renal cell carcinoma, or pancreatic neuroendocrine tumors

8/12/2015

OPEN

NTRK Fusions
(0.10% frequency)

Z1E

35 (14)

larotrectinib

None

3/13/2017

OPEN

PTEN Loss by Immunohistochemistry without PIK3CA Mutations
(1.93% frequency)
 
 Z1G 35 (18) copanlisib  Indolent non-Hodgkin’s lymphoma, diffuse large B cell lymphoma, or HER2-positive breast cancer  6/20/2018  OPEN
AKT mutations
(0.77% frequency)
 Z1K 35 (30) ipatasertib  None 7/25/2019  OPEN 
CDK4 or CDK6 amplification
(1.36% frequency)
 Z1C 49 (36) Ibrance®
(palbociclib)
Breast cancer, mantel cell lymphoma, liposarcoma, or myeloma 3/13/2017
OPEN 
Non-V600 BRAF mutations
(0.80% frequency)
 Z1L 35 (35) ulixertinib (BVD-523)  None 7/25/2019  OPEN